When clinicians and pathologists argue, sometimes genetics can settle the dispute. How about DLB?
How α-synuclein aggregates spread, quite possibly starting in the nose in some people, sets DLB apart from its better-known cousins, Alzheimer’s and Parkinson’s.
In dementia with Lewy bodies, basic scans are used in routine diagnosis. Multimodal imaging and new PET tracers for affected neurotransmitters of pathological deposits in the brain and gut are entering research settings.
At a DLB meeting, scientists reported progress in disentangling the notorious overlap in symptoms and pathology in this quintessential spectrum disease. (Hint: tangles are bad.)
Studies find that a drug in cough syrup can improve symptoms, and that radiation therapy safely shuts off a salivary gland.
At the International Dementia with Lewy Bodies conference in Fort Lauderdale, Florida, fuzzy images of dying sympathetic cardiac nerve terminals proved to be a sharp aide to clinch this notoriously difficult diagnosis.
At their international conference, DLB researchers demonstrated progress in defining a distinct identify for this Alzheimer’s-Parkinson’s overlap disease. This has helped prepare DLB for more therapeutics trials.
Trials of gene therapy for spinomuscular atrophy and stem cell treatments for ALS look promising.
Computerized assessments and electroencephalography both hold promise for diagnosis and drug testing in Alzheimer’s disease, but the Food and Drug Administration does not yet know how to oversee the technology.
In various animal models of traumatic brain injury, acute treatments quiet inflammation and preserve neurons and their myelin sheaths.
Researchers at this year’s SfN meeting detailed different strategies and outcomes of passive and active vaccines.
The leaders of two large European trials report that promoting cardiac health, exercise, and mental activity helped maintained cognition in older adults.
Forget transgenics for a moment. Large collections of inbred and outbred mice could be an untapped treasure trove for Alzheimer’s researchers.
At CTAD, investigational Phase 1 drugs include a repackaged and a new anti-amyloid, a tau vaccine, and a repurposed cancer drug.
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.